Figure 2 | Blood Cancer Journal

Figure 2

From: The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Figure 2

Pracinostat potently inhibits cell proliferation in AML cell lines and primary AML cells. (a) IC50 of cell lines tested in 48 h cell proliferation assays (CellTiterGlo); FAB: French–American–British classification of AML cells. Results show mean±s.d. from at least three rounds of experiments, each performed in triplicates. (b) Primary AML blasts from 16 patients were expanded and then treated on d12–d13 with dimethyl sulfoxide or pracinostat serially diluted in nine steps from 10 μM to 1.5 nM for 48 h. Results show means from two rounds of blast expansion/proliferation assays. Gray-shaded icons depict blast cells carrying the FLT3-ITD.

Back to article page